Related Experiment Videos
[Chemotherapy for hepatocellular carcinoma].
Takuji Okusaka1, Hideki Ueno, Masafumi Ikeda
1Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 5, 2005
Summary
Hepatocellular carcinoma (HCC) often recurs early after treatment. Effective systemic chemotherapy is crucial for improving survival in HCC patients, as current options show limited impact.
Area of Science:
- Hepatocellular carcinoma (HCC) research
- Oncology
- Systemic therapy development
Context:
- Early recurrence of HCC is common post-resection and ablation.
- Multiple HCCs and metastasis at diagnosis present significant challenges.
- Existing treatments offer limited survival benefits for advanced HCC.
Purpose:
- To highlight the need for effective systemic treatments for HCC.
- To underscore the limitations of current chemotherapeutic regimens.
- To emphasize the ongoing search for improved HCC therapies.
Summary:
- Hepatocellular carcinoma (HCC) patients frequently experience early recurrence.
- Systemic chemotherapy is essential for improving overall survival in HCC.
- Current chemotherapeutic agents lack reproducible high response rates and significant survival impact.
Impact:
- Identifies a critical unmet need in HCC treatment.
- Guides future research towards developing more effective systemic therapies.
- Informs clinical practice regarding the limitations of current chemotherapy for HCC.